288 related articles for article (PubMed ID: 21328427)
1. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
2. [CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka Y
Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
[No Abstract] [Full Text] [Related]
3. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
4. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
5. [Rituximab and hematological malignancy].
Hatake K; Mishima Y; Terui Y
Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
[TBL] [Abstract][Full Text] [Related]
7. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
Hansen PB; Hasselbalch HC
Ugeskr Laeger; 2004 Feb; 166(6):466-9. PubMed ID: 15045710
[No Abstract] [Full Text] [Related]
9. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
11. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: current status as therapy for malignant and benign hematologic disorders.
Abdulla NE; Ninan MJ; Markowitz AB
BioDrugs; 2012 Apr; 26(2):71-82. PubMed ID: 22339395
[TBL] [Abstract][Full Text] [Related]
14. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of pemphigus with rituximab].
Li J; Zheng HY; Liu YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):107-10. PubMed ID: 19317073
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
17. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
18. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis.
Amital A; Dux S; Shitrit D; Shpilberg O; Kramer MR
Thorax; 2010 Nov; 65(11):1025-6. PubMed ID: 20855439
[TBL] [Abstract][Full Text] [Related]
20. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
